Start4All - Start Taking Action for TB Diagnosis (DARE-TB)

DARE-TB has been designed to address critical evidence gaps on the diagnostic performance and operational value of near point-of-care (NPOC) nucleic acid amplification tests (NAATs) within community-based case finding (CBCF) strategies. Although World Health Organization (WHO) recommends wider access to molecular testing, its use remains concentrated in facility-based settings well short of the global targets and largely dependent on sputum production. This creates a substantial diagnostic gap for people reached through community screening who either cannot provide sputum or whose sputum specimens cannot be tested on a NAAT at a facility, particularly for marginalized, hard-to-reach populations with poor access to healthcare.

NCT Number	NCT07420881
Lead Sponsor	Liverpool School of Tropical Medicine Collaborators: Centre for Control of Chronic Disease (CCCD),icddr,b, Comité National d'Ethique pour la Recherche en Santé Humaine, National Health Research Ethics Committee Nigeria
Conditions	TB - Tuberculosis
Enrollment	60,000 participants
Start Date	2026-03-01
Primary Completion	2027-03-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2026-02-19